These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27736849)

  • 1. The effect of removing funding restrictions for atorvastatin differed across sociodemographic groups among New Zealanders hospitalised with cardiovascular disease: a national data linkage study.
    Mehta S; Wells S; Jackson R; Harrison J; Kerr A
    N Z Med J; 2016 Oct; 129(1443):18-29. PubMed ID: 27736849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of Special Authority requirements for clopidogrel improved optimal care following percutaneous coronary intervention across sociodemographic groups.
    Mehta S; Wells S; Jackson R; Harrison J; Kerr A
    N Z Med J; 2015 Mar; 128(1411):34-42. PubMed ID: 25820501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1).
    Kerr A; Exeter D; Hanham G; Grey C; Zhao J; Riddell T; Lee M; Jackson R; Wells S
    N Z Med J; 2014 Aug; 127(1400):39-69. PubMed ID: 25145366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis.
    Metcalfe S; Laking G; Arnold J
    N Z Med J; 2013 Oct; 126(1384):14-41. PubMed ID: 24162628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study.
    Lawes CM; Thornley S; Young R; Hopkins R; Marshall R; Chan WC; Jackson G
    Prim Care Respir J; 2012 Mar; 21(1):35-40. PubMed ID: 22218819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).
    Mehta S; Wells S; Riddell T; Kerr A; Pylypchuk R; Marshall R; Ameratunga S; Chan WC; Thornley S; Crengle S; Harrison J; Drury P; Elley CR; Bell F; Jackson R
    J Prim Health Care; 2011 Jun; 3(2):93-101. PubMed ID: 21625656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
    Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM
    Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equity in statin use in New Zealand.
    Norris P; Horsburgh S; Becket G; Keown S; Arroll B; Lovelock K; Crampton P; Cumming J; Herbison P
    J Prim Health Care; 2014 Mar; 6(1):17-22. PubMed ID: 24624407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event.
    Thornley S; Marshall R; Chan WC; Kerr A; Harrison J; Jackson G; Crengle S; Wright C; Wells S; Jackson R
    Eur J Prev Cardiol; 2012 Jun; 19(3):349-57. PubMed ID: 21450568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographic differences in the initiation and maintenance of statins in the first year post ACS in New Zealand: a data linkage study (ANZACS-QI 57).
    Muniandy A; Lee M; Grey C; Ferrier K; Kerr AJ
    N Z Med J; 2021 Apr; 134(1534):31-45. PubMed ID: 33927436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions.
    Robinson T; Jackson R; Wells S; Kerr A; Marshall R
    N Z Med J; 2017 Oct; 130(1463):28-38. PubMed ID: 28981492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethnic and socioeconomic disparities in the prevalence of cardiovascular disease in New Zealand.
    Chan WC; Wright C; Riddell T; Wells S; Kerr AJ; Gala G; Jackson R
    N Z Med J; 2008 Nov; 121(1285):11-20. PubMed ID: 19079433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
    Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
    Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of generic substitution on refill adherence to statin therapy: a nationwide population-based study.
    Trusell H; Sundell KA
    BMC Health Serv Res; 2014 Dec; 14():626. PubMed ID: 25475416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and use of mapping techniques to describe the geographical distribution of medication dispensing for the secondary prevention of atherosclerotic CVD in New Zealand: VIEW-2.
    Exeter DJ; Zhao J; Hanham G; Grey C; Wells S; Kerr A
    N Z Med J; 2014 Aug; 127(1400):70-80. PubMed ID: 25145367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.
    Soedamah-Muthu SS; Livingstone SJ; Charlton-Menys V; Betteridge DJ; Hitman GA; Neil HA; Bao W; DeMicco DA; Preston GM; Fuller JH; Stehouwer CD; Schalkwijk CG; Durrington PN; Colhoun HM;
    Diabetologia; 2015 Jul; 58(7):1494-502. PubMed ID: 25899452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.